Clinical TrialApr 27, 2026, 07:01 PM
MNOV: Study identifies MN-166 potential for brain metastasis
AI Summary
MediciNova, Inc. announced that a study published in "Cancer Research" identified a central vulnerability in brain metastasis and demonstrated the potential of its lead product, MN-166 (ibudilast), to address it. The research showed that MN-166 can effectively block MIF–CD74 signaling, reverse pro-metastatic immune reprogramming, and suppress brain metastasis growth in preclinical systems. These findings provide a strong rationale for pursuing biomarker-driven clinical strategies, and MediciNova plans to collaborate on future clinical research for patients with brain metastases.
Key Highlights
- A study identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74-positive microglia and macrophages as a central vulnerability in brain metastasis.
- Research published in the peer-reviewed journal "Cancer Research" (March 2026).
- Pharmacological modulation of this pathway was demonstrated using the brain-penetrant small molecule ibudilast (MN-166).
- Inhibition of the MIF–CD74 signaling axis significantly reduced metastatic progression in experimental models and patient samples.
- Secreted MIF was identified as a candidate liquid biopsy biomarker detectable in cerebrospinal fluid.
- MN-166 (ibudilast) effectively blocked MIF–CD74 signaling, reversed pro-metastatic immune reprogramming, and suppressed brain metastasis growth.
- MediciNova plans to collaborate with CNIO on future clinical research for patients with solid tumors having brain metastases.
- MediciNova holds granted patents covering MN-166 for preventing and minimizing cancer metastasis across multiple solid tumor types.
Price Impact
More from MNOV